Malignant Mesothelioma Epidemiology Market Report
The Global Malignant Mesothelioma Epidemiology Market is segmented, By Type (Malignant Pleural Mesothelioma , Malignant Peritoneal Mesothelioma , Malignant Pericardial Mesothelioma), Drug Type (Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Vinorelbine, Others), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Oncology Centers) and Region. This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global Malignant Mesothelioma Epidemiology market. The historic years considered for the study are 2016-2019, the base year is 2020, the estimated year is 2021, and the forecast period is 2022-2026.
The Global Malignant Mesothelioma Epidemiology Market is segmented, By Type (Malignant Pleural Mesothelioma , Malignant Peritoneal Mesothelioma , Malignant Pericardial Mesothelioma), Drug Type (Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Vinorelbine, Others), Route of Administration (...
Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.
Note: The summary below might not have included insights on covid impact since we have large number of reports.
The Global Malignant Mesothelioma Epidemiology Market is expected to grow from USD 380.2 million in 2020 to USD 540.8 million by 2026 at a CAGR of over 6.2% during the forecast period.
Figure: Global Malignant Mesothelioma Epidemiology Market Size, 2020-2026 (USD Million)
Malignant mesothelioma is known as rare cancer that originates from the inner lining of the body’s serous cavities i.e., peritoneum, pleura, pericardium, and vaginal tunic of the testicle. It is caused due to asbestos exposure which can be hidden in the living area or any other object such as curtains, cardboard, toys, and board covers among others.
Key players operating in the global Malignant Mesothelioma Epidemiology Market are
The growth of the global malignant mesothelioma epidemiology market is primarily driven by increasing cases of mesothelioma cancer due to asbestos exposure.
Based on drug type, the market has been segmented into pemetrexed, cisplatin, carboplatin, gemcitabine, vinorelbine, and others.
The pemetrexed segment accounted for the largest market share in 2020 and is expected to register significant growth over the forecast period. The segment growth can be attributed to the increasing use of pemetrexed drugs in combination with other drugs.
Geographically, the market in North America accounted for the largest market share in 2020 and is expected to continue its dominance over the forecast period owing to the increasing incidence of cancer disease.
The covid-19 outbreak posed significant challenges to the health care system across geographies. It affected the growth of the malignant mesothelioma epidemiology market negatively as patients postponed their treatment due to a rapid surge in covid-19 cases across geographies. Also, supply chain disruptions due to the imposition of lockdown affected the installation of equipment in the hospital and thus, affected the market growth.
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].
The malignant mesothelioma epidemiology market size is expected to reach USD 540.8 million in the foreseeable future.
AstraZeneca plc (UK), Bristol-Myers Squibb Company (The U.S), F. Hoffmann-La Roche AG (Switzerland), Merck & Co., Inc. (The U.S), Novartis International AG (Switzerland), Pfizer Inc. (The U.S), Sanofi S.A. (France), Eli Lilly and Company (The U.S), Teva Pharmaceutical Industries Ltd (Israel), C.H. Boehringer Sohn AG & Ko. KG (Germany), Mylan N.V. (The U.S), Fresenius Kabi AG (Germany) and Sun Pharmaceuticals Industries Ltd (India) are among the key players in the malignant mesothelioma epidemiology market.
The malignant mesothelioma epidemiology market is expected to witness an impressive growth of 6.2% CAGR in the coming years.
North America is expected to remain dominant in the malignant mesothelioma epidemiology market during the next five years.
The pemetrexed segment accounted for the largest market share in 2020 and is expected to register significant growth.
Increasing cases of mesothelioma cancer due to asbestos exposure, rising geriatric populace across geographies, growing emphasis on the development of more advanced cancer treatment methods are the factors driving the growth of malignant mesothelioma epidemiology market.
Malignant mesothelioma epidemiology manufacturers, Malignant mesothelioma epidemiology suppliers, Malignant mesothelioma epidemiology distributors, Organizations, Government bodies are the target audience in te malignant mesothelioma epidemiology market.